DOP2006000217A - Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica - Google Patents

Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica

Info

Publication number
DOP2006000217A
DOP2006000217A DO2006000217A DO2006000217A DOP2006000217A DO P2006000217 A DOP2006000217 A DO P2006000217A DO 2006000217 A DO2006000217 A DO 2006000217A DO 2006000217 A DO2006000217 A DO 2006000217A DO P2006000217 A DOP2006000217 A DO P2006000217A
Authority
DO
Dominican Republic
Prior art keywords
alkylene
alkyl
aryl
nrarb
optionally substituted
Prior art date
Application number
DO2006000217A
Other languages
English (en)
Inventor
Gilles Courtemanche
Jean Michel Augereau
Geslin Michel
Laurence Serva
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2006000217A publication Critical patent/DOP2006000217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a los derivados de la 1-amino-ftalazina. de la formula general A, B = alquileno(C1-4,) opcionalmente sustituido; L = union simple o un alquileno(C1-2), -CH=CH- o -C=C-; estando los grupos alquileno(C1-2) y -CH=CH opcionalmente sustituidos, o bien L = cicloprop-1,2-diilo; R = H o alquilo(C1-5), fluoroalquilo(C1-3), cicloalquilo(C3-6), -C(O)alquilo(C1-3), alquileno(C1-3)-cicloalquilo(C3-6), - CH2-C=-CH , alquileno(C2-3)-NRaRb, alquileno(C1-3)-X-alquilo(C1-3) con X = 0, SO2; R1 = arilo o un heteroarilo, opcionalmente sustituidos; R2, R3 = H, alquilo(C1-3) o fluoroalquilo(C1-3), o bien R2 y R3 forman juntos un cicloprop-1,1-diilo; R4 = H o un alquilo(C1-5), fluoroalquilo(C1-3), cicloalquilo(C3-6), alquileno(C1-3)-cicloalquilo(C3-6), alquileno(C1-3)-O-alquilo(C1-3), o R4 = alquileno(C1-3)-(OH), alquileno(C1-3)-X-alquilo(C1-3) donde X = S, SO o SO2, o R4 = heterociclo, grupo alquileno(C1-3)-NRaRb, arilo, alquileno(C1-3)-arilo, -0-arilo, alquileno(C1-3)-O-arilo, alquileno(C1-3)-O-alquileno(C1-3)arilo, heteroarilo o alquileno(C1-3)-heteroarilo, opcionalmente sustituidos; R5 = H, halogeno o un alquilo(C1-5), fluoroalquilo(C1-3), alcoxi(C1-5), fluoroalcoxi(C1-3), alquileno(C1- 3)-(OH), -CN, -X-alquilo(C1-3) donde X = S, SO o S02, o R5 = -NRaRb, alquileno(C1-3)NRaRb, arilo, alquileno(C1-3)-arilo, -0-arilo o heteroarilo, opcionalmente sustituidos; R, = H, halogeno o un alquilo(C1-5), fluoroalquilo(C1-3), alcoxi(C1-5), -COON, -C(O)O-alquilo(C1-5), fluoroalcoxi(C1-3), alquileno(C1-3)-(OH), -CN, -X-alquilo(C1-3) donde X representa S, SO o 502, o R, = -NRaRb, alquileno(C1-3)-NRaRb, -C(O)-NRaRb, -C(O)-alquilo(C1-3), arilo, -0 arilo o heteroarilo, opcionalmente sustituidos; en forma de base o de sal de adición de acido, asi como en forma de hidrato o de solvato. Procedimiento para la preparacion y aplicacion en terapeutica.
DO2006000217A 2005-10-12 2006-10-12 Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica DOP2006000217A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510408A FR2891828B1 (fr) 2005-10-12 2005-10-12 Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
DOP2006000217A true DOP2006000217A (es) 2007-05-15

Family

ID=36623451

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000217A DOP2006000217A (es) 2005-10-12 2006-10-12 Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica

Country Status (10)

Country Link
US (1) US20090124624A1 (es)
EP (1) EP1940823A2 (es)
JP (1) JP2009511552A (es)
AR (1) AR057980A1 (es)
DO (1) DOP2006000217A (es)
FR (1) FR2891828B1 (es)
GT (1) GT200600455A (es)
PE (1) PE20070550A1 (es)
TW (1) TW200800208A (es)
WO (1) WO2007042660A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2016123796A1 (en) * 2015-02-06 2016-08-11 Abbvie Inc. Substituted phthalazines
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2022253326A1 (zh) * 2021-06-05 2022-12-08 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
AU2022355409A1 (en) * 2021-09-30 2024-05-09 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226269A (ja) * 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2003070244A1 (en) * 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
JP2005532368A (ja) * 2002-06-12 2005-10-27 アボット・ラボラトリーズ メラニン濃縮ホルモン受容体の拮抗薬
WO2004052371A2 (en) * 2002-12-11 2004-06-24 7Tm Pharma A/S Cyclic quinoline compounds for use in mch receptor related disorders
US7605176B2 (en) * 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1771175B1 (en) * 2004-06-30 2015-12-23 Janssen Pharmaceutica NV Phthalazine derivatives as parp inhibitors

Also Published As

Publication number Publication date
WO2007042660A2 (fr) 2007-04-19
WO2007042660A3 (fr) 2007-05-31
PE20070550A1 (es) 2007-06-19
EP1940823A2 (fr) 2008-07-09
TW200800208A (en) 2008-01-01
JP2009511552A (ja) 2009-03-19
GT200600455A (es) 2007-05-28
AR057980A1 (es) 2008-01-09
FR2891828A1 (fr) 2007-04-13
FR2891828B1 (fr) 2007-12-21
US20090124624A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
DOP2006000217A (es) Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica
DOP2005000062A (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicación en terapeutica
MEP22308A (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
MY156034A (en) Mesoionic pesticides
WO2007042669A3 (fr) DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl
EA200802389A1 (ru) Азиридинилэпотилоновые соединения
AR049139A1 (es) Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii.
IN2012DN00573A (es)
PE20090042A1 (es) Analogos de ciclopamina
TNSN06408A1 (en) Enantioselektive preparation of quinoline derivative
DE3855461D1 (de) Methyl 2-[2-(3-substituierte phenoxy)pyridin-3-yl]-3-methoxypropenoate und ihre Verwendung als pilztötendes Mittel
AR062100A1 (es) Compuestos y composiciones como moduladores de la senda de hedgehog
ATE517885T1 (de) Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
BRPI0601311A (pt) mercaptosilanos
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR049138A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
WO2003039451A3 (en) Thiazole pyridazinones as adenosine antagonists
AR058701A1 (es) Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos
GB0501964D0 (en) Chemical compounds
AR089221A1 (es) Disales de acido malonico y metodo para preparar diahaluros de malonilo
TW200502225A (en) Heterocyclic compounds useful as nurr-1 activators
AR056689A1 (es) Derivados de 1- amino-isoquinolina, su preparacion y su aplicacion en terapeutica